ALC vs RYTM
Alcon Inc vs Rhythm Pharmaceuticals, Inc. — AI-powered side-by-side comparison
VS
RYTM
Rhythm Pharmaceuticals, Inc.
62
Buy
| Metric | ALC | RYTM |
|---|
| AI Score |
68
|
62
|
| Price |
$75.39
|
$112.61
|
| P/E Ratio |
45.39×
|
-36.28×
|
| ROE |
4.4%
|
-72.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
89.0%
|
| Debt / Equity |
0.24×
|
0.02×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
59.9
|
| Beta |
0.703
|
1.974
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus RYTM.
ALC leads by 6 points.
ALC scores 68/100 (Buy) versus RYTM at 62/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
RYTM Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 53.5% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 16.3% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 53.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 26.5x prices in significant intangible value — Value
- ROE of only -80.5% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 16.3% signals elevated volatility — Risk